Literature DB >> 33806425

Development of Novel Follicular Thyroid Cancer Models Which Progress to Poorly Differentiated and Anaplastic Thyroid Cancer.

Caitlin O Caperton1, Lee Ann Jolly1, Nicole Massoll2, Andrew J Bauer3, Aime T Franco3.   

Abstract

Recent developments in thyroid cancer research have been hindered by a lack of validated in vitro models, allowing for preclinical experimentation and the screening of prospective therapeutics. The goal of this work is to develop and characterize three novel follicular thyroid cancer (FTC) cell lines developed from relevant animal models. These cell lines recapitulate the genetics and histopathological features of FTC, as well as progression to a poorly differentiated state. We demonstrate that these cell lines can be used for a variety of in vitro applications and maintain the potential for in vivo transplantation into immunocompetent hosts. Further, cell lines exhibit differing degrees of dysregulated growth and invasive behavior that may help define mechanisms of pathogenesis underlying the heterogeneity present in the patient population. We believe these novel cell lines will provide powerful tools for investigating the molecular basis of thyroid cancer progression and lead to the development of more personalized diagnostic and treatment strategies.

Entities:  

Keywords:  Hras; MAPK; PI3K; cell lines; follicular thyroid cancer; thyroid cancer

Year:  2021        PMID: 33806425      PMCID: PMC7961488          DOI: 10.3390/cancers13051094

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  29 in total

1.  Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers.

Authors:  Rebecca E Schweppe; Nikita Pozdeyev; Laura A Pike; Christopher Korch; Qiong Zhou; Sharon B Sams; Vibha Sharma; Umarani Pugazhenthi; Christopher Raeburn; Maria B Albuja-Cruz; Philip Reigan; Daniel V LaBarbera; Iñigo Landa; Jeffrey A Knauf; James A Fagin; Bryan R Haugen
Journal:  Mol Cancer Res       Date:  2019-02-07       Impact factor: 5.852

2.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

Review 3.  Sorafenib for the treatment of thyroid cancer: an updated review.

Authors:  Jolanta Krajewska; Daria Handkiewicz-Junak; Barbara Jarzab
Journal:  Expert Opin Pharmacother       Date:  2015-01-21       Impact factor: 3.889

Review 4.  Biologic and Clinical Perspectives on Thyroid Cancer.

Authors:  James A Fagin; Samuel A Wells
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

5.  RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact.

Authors:  Marco Volante; Ida Rapa; Manoj Gandhi; Gianni Bussolati; Daniela Giachino; Mauro Papotti; Yuri E Nikiforov
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

6.  Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

Authors:  Vivek Subbiah; Robert J Kreitman; Zev A Wainberg; Jae Yong Cho; Jan H M Schellens; Jean Charles Soria; Patrick Y Wen; Christoph Zielinski; Maria E Cabanillas; Gladys Urbanowitz; Bijoyesh Mookerjee; Dazhe Wang; Fatima Rangwala; Bhumsuk Keam
Journal:  J Clin Oncol       Date:  2017-10-26       Impact factor: 44.544

7.  Downregulated expression of TSHR is associated with distant metastasis in thyroid cancer.

Authors:  Tianrun Liu; Qianqian Men; Xuan Su; Weichao Chen; Lan Zou; Qiuli Li; Ming Song; Dian Ouyang; Yanfeng Chen; Zhaoqu Li; Xiaoyan Fu; Ankui Yang
Journal:  Oncol Lett       Date:  2017-10-03       Impact factor: 2.967

8.  Pitfall in immunohistochemical staining for thyroglobulin in case of thyroid metastasis from lung carcinoma.

Authors:  Napatt Kanjanahattakij; Palapong Chayangsu; Wasana Kanoksil; Sasiphat Chontong; Chutintorn Sriphrapradang
Journal:  Cytojournal       Date:  2015-11-30       Impact factor: 2.091

Review 9.  Therapeutic advances in anaplastic thyroid cancer: a current perspective.

Authors:  Shikha Saini; Kiara Tulla; Ajay V Maker; Kenneth D Burman; Bellur S Prabhakar
Journal:  Mol Cancer       Date:  2018-10-23       Impact factor: 27.401

Review 10.  Multikinase Inhibitor Treatment in Thyroid Cancer.

Authors:  Ole Vincent Ancker; Marcus Krüger; Markus Wehland; Manfred Infanger; Daniela Grimm
Journal:  Int J Mol Sci       Date:  2019-12-18       Impact factor: 5.923

View more
  1 in total

1.  Advances in Thyroid Carcinoma.

Authors:  Iñigo Landa
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.